25658-36-0

Basic information

• Product Name: Dimethyl 2,4-pyridinedicarboxylate
• Synonyms: 2,4-Pyridinedicarboxylic acid dimethyl ester;Dimethyl 2,4-pyridinedicarboxylate;Nsc78960;diMethyl pyridine-2,4-dicarboxylate;2,4-pyridine dicarboxylic acid 2,4-diMethyl ester;Dimethyl 2,4-Pyridinedicarboxylate Pyridine-2,4-Dicarboxylic Acid Dimethyl Ester;2,4-PYRIDINEDICARBOXYLIC ACID,DIMETHYL ESTER(6Cl,7Cl,8Cl,9Cl)
• CAS NO: 25658-36-0
• Molecular Formula: C9H9NO4
• Molecular Weight: 195.18
• Mol File: 25658-36-0.mol
• Article Data: 10

Chemical Properties

• Melting Point: 252-253 °C(Solv: water (7732-18-5))
• Boiling Point: 302.5°Cat760mmHg
• Flash Point: 136.8°C
• Appearance: /
• Density: 1.231g/cm³
• Vapor Pressure: 0.000984mmHg at 25°C
• Refractive Index: 1.516
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -0.96±0.10(Predicted)
• CAS DataBase Reference: Dimethyl 2,4-pyridinedicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Dimethyl 2,4-pyridinedicarboxylate(25658-36-0)
• EPA Substance Registry System: Dimethyl 2,4-pyridinedicarboxylate(25658-36-0)

Safety Data

• Hazardous Substances Data: 25658-36-0(Hazardous Substances Data)

Usage

Description

Dimethyl 2,4-pyridinedicarboxylate, a chemical compound with the molecular formula C10H10N2O4, is an ester of 2,4-pyridinedicarboxylic acid. It is a colorless to light yellow liquid with a fruity odor, insoluble in water, and soluble in most organic solvents. This relatively stable compound is commonly used as a pharmaceutical intermediate in the synthesis of various drugs.

Uses

Used in Pharmaceutical Industry:
Dimethyl 2,4-pyridinedicarboxylate is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique chemical structure and properties make it a valuable component in the development of new medications.
As a Chemical Intermediate:
Dimethyl 2,4-pyridinedicarboxylate is utilized as a chemical intermediate in the production of various pharmaceutical compounds. Its reactivity and compatibility with other chemical entities allow for the creation of a wide range of drug molecules.
It is important to handle Dimethyl 2,4-pyridinedicarboxylate with care, as it may react violently with strong oxidizing agents. Following proper safety protocols is essential when working with this chemical compound.

InChI:InChI=1/C9H9NO4/c1-13-8(11)6-3-4-10-7(5-6)9(12)14-2/h3-5H,1-2H3

Upstream product

• 186581-53-3 diazomethane 
• 499-80-9 pyridine-2,4-dicarboxylic acid 
• 67-56-1 methanol 
• 57062-14-3 pyridine-2,4-bis(carbonyl)chloride 
• 149-73-5 trimethyl orthoformate 

Downstream Products

• 160601-84-3 2-carbamoylpyridine-4-carboxylic acid 
• 153559-43-4 methyl 2-(chlorocarbonyl)isonicotinate 

Relevant articles and documents

Change of Orientation in Photoreaction by Oxygen. Effect of Oxygen on Photo-methoxylation of Dimethyl Ester of 2,4- and 3,4-Pyridinedicarboxylic Acid

The UV-irradiation of dimethyl 2,4- and 3,4-pyridinedicarboxylates in methanol in the presence of H2SO4 under O2 brings about methoxylation at the β-position of the pyridine ring, while under N2 methoxylation occurs at the α-position.

Multiprotein Dynamic Combinatorial Chemistry: A Strategy for the Simultaneous Discovery of Subfamily-Selective Inhibitors for Nucleic Acid Demethylases FTO and ALKBH3

Dynamic combinatorial chemistry (DCC) is a powerful supramolecular approach for discovering ligands for biomolecules. To date, most, if not all, biologically templated DCC systems employ only a single biomolecule to direct the self-assembly process. To expand the scope of DCC, herein, a novel multiprotein DCC strategy has been developed that combines the discriminatory power of a zwitterionic “thermal tag” with the sensitivity of differential scanning fluorimetry. This strategy is highly sensitive and could differentiate the binding of ligands to structurally similar subfamily members. Through this strategy, it was possible to simultaneously identify subfamily-selective probes against two clinically important epigenetic enzymes: FTO (7; IC50=2.6 μm) and ALKBH3 (8; IC50=3.7 μm). To date, this is the first report of a subfamily-selective ALKBH3 inhibitor. The developed strategy could, in principle, be adapted to a broad range of proteins; thus it is of broad scientific interest.

DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS

The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.